



## A VISION FOR THE CHILDREN'S ONCOLOGY GROUP

Doug Hawkins, MD 11:00 AM - 11:30 PM Virtual

### BIO

Douglas S. Hawkins, MD, is currently the Hematology/Oncology Division Chief at Seattle Children's Hospital and Professor of Pediatrics at the University of Washington School of Medicine. After receiving his MD from Harvard Medical School in 1990, he moved to Seattle for his pediatric residency and pediatric hematology/oncology fellowship training. He joined the University of Washington faculty in 1996, where he has spent his entire academic career.

Dr. Hawkins has been the Chair of the COG Soft Tissue Sarcoma Committee since 2008 and a member of the COG Bone Tumor Steering Committee. He also chairs the COG Scientific and Discipline Chairs Committee. His clinical research has focused on the biology and treatment of pediatric sarcomas. He has been the chair of two COG clinical trials, one for Ewing sarcoma (AEWS0331) and another for rhabdomyosarcoma (ARST0531). He chairs the international EURO EWING Consortium External Advisory Board and is the Chair of the Data Monitoring Committee for the European Frontline and Relapse in RhabdoMyoSarcoma Study (FaR-RMS). He has been an author of more than 180 peer-reviewed manuscripts, textbook chapters, or invited commentaries.



## MODERATOR - THE RACE ACT ON THE EVE OF IMPLEMENTATION

Stacey Adam, PhD 11:30 AM - 12:15 PM Virtual

### BIO

Stacey Adam is the Director of Cancer Research Partnerships at the Foundation for the NIH (FNIH). The major partnerships she oversees at FNIH are the Partnership for Accelerating Cancer Therapies (PACT), the Lung Master protocol (Lung-MAP) clinical trial, and the Cancer Steering Committee of the Biomarkers Consortium. She also oversees the design and startup of new public-private partnerships, such as the Preclinical Pediatric Oncology Partnership and a few outside the cancer portfolio. Prior to FNIH, Dr. Adam was a Manager at Deloitte Consulting within the Federal Life Sciences and Healthcare Strategy practice where she supported many federal and non-profit client projects. Before Deloitte, Dr. Adam conducted her postdoctoral fellowship at Stanford University School of Medicine, Department of Oncology and her Ph.D. in Pharmacology/Toxicology at Duke University, where during both she worked creating better animal models for drug development to treat cancer.



## **PANELIST - THE RACE ACT ON THE EVE OF IMPLEMENTATION**

Martha Donoghue, MD 11:30 AM - 12:15 PM Virtual

### **BIO**

Martha Donoghue is the Acting Deputy Director of the Division of Oncology 2 in the Office of Oncologic Diseases at the U.S. Food and Drug Administration (FDA). Dr. Donoghue provides regulatory oversight, engages in clinical review activities, and provides advice to stakeholders on the clinical development of drugs and therapeutic biologics for the diagnosis, prevention, and treatment of cancer. Dr. Donoghue also serves on several FDA and external working groups aimed at expediting development of treatments for pediatric and adult patients with cancer. Areas of special interest include development of treatments for rare cancers and the use of innovative designs and clinical outcome assessments in clinical trials to optimize drug development. Prior to joining FDA in 2009, Dr. Donoghue completed a fellowship in Pediatric Hematology and Oncology at the Children's National Medical Center after working for several years as a general pediatrician in private practice. She received her medical degree from Emory University and completed a residency in general pediatrics at the Georgetown University Medical Center.




## PANELIST - THE RACE ACT ON THE EVE OF IMPLEMENTATION

Mark Kieran, MD 11:30 am - 12:15 PM Virtual

### BIO

Dr. Kieran is currently the Senior Director of Pediatric Oncology, Bristol-Myers Squibb. He received a PhD in Immunology in 1983 from the University of Alberta, Edmonton, Canada, and his MD in 1986 from the University of Calgary. After a post-doctoral fellowship in the Department of Molecular Biology at the Pasteur Institute in Paris, France where he cloned the regulatory molecule NFkB, he completed a pediatric residency at McGill University in Montreal and a pediatric oncology fellowship at Boston Children's Hospital. Dr. Kieran was named Director of Pediatric Neuro-Oncology at the Dana-Farber Cancer Institute in 1998 until his move to BMS in 2018. While in Boston, he developed a large number of first in pediatric clinical trials in the areas of targeted therapeutics, gene therapy, anti-angiogenic modalities and immunotherapy. His ongoing interests include the genomic identification of mutations and incorporation of targeted, biologic, immune and gene therapy for children with cancer. He is currently also on the Medical Staff at Children's Hospital of Philadelphia.



## PANELIST - THE RACE ACT ON THE EVE OF IMPLEMENTATION

Malcolm Smith, MD 11:30 AM - 12:15 PM Virtual

### BIO

Dr. Smith is Associate Branch Chief, Pediatrics, in the Cancer Therapy Evaluation Program (CTEP), NCI. Dr. Smith has been a member of CTEP since 1990 and during his years at CTEP has focused on developing NCI's preclinical and clinical research programs for children with cancer. Dr. Smith serves as the Program Director and primary NCI liaison to childhood cancer researchers in the Children's Oncology Group (COG), focusing primarily on hematologic malignancies and brain cancers. He also serves as the Program Director for the Pediatric Early Phase Clinical Trials Network (PEP-CTN), the Pediatric Brain Tumor Consortium, and the Pediatric Preclinical Testing Consortium. Dr. Smith has served as NCI co-leader of the Childhood Cancer TARGET Initiative, a program using modern genomics technologies to identify childhood cancer genomic alterations. He is a co-leader of the NCI Moonshot Fusion Oncoproteins in Childhood Cancers Implementation Team and a member of the Pediatric Immunotherapy Implementation Team. Dr. Smith serves as a member of the Editorial Board of *Pediatric Blood and Cancer* and of the NCI PDQ Pediatric Editorial Board.